As I see it

Share this article:
As the Obama transition team focuses on the nation's highest priorities, don't think for a moment that drug marketing issues will get a pass come Inauguration Day.

With healthcare promises near the top of his agenda, expect Obama operatives to work closely with Capitol Hill counterparts to undo the prohibition on negotiating Medicare drug prices, even if work on the national deficit diverts attention from the notorious “doughnut hole” in seniors' drug benefits.

Although there was hardly any mention of the FDA on the campaign trail, Team Obama's reforms for that agenda will be set by Democrats on Capitol Hill who have a laundry list of things to change, including the composition of outside advisory committees to lessen industry influences, attention to drug safety in the early phases of new product development and review, and more attention to whistleblower complaints.

A Supreme Court decision favoring industry in Wyeth v. Levine is likely to provoke swift congressional countermeasures if it gives the FDA blanket pre-emption authority like that awarded last February for medical device makers. Nevertheless, readers of Supreme Court judicial banter tea leaves have a poor batting average when it comes to predicting case outcomes, so when the decision comes down, Democratic bills to answer it will be ready, and to undo the device preemption decision in Riegel v. Medtronic as well.

And as one anonymous but apparently informed FDA blogger put it, the core issue in Wyeth v. Levine wasn't the failure of the FDA-approved label to warn, but its failure to contraindicate the IV-push technique that caused the harm.

James G. Dickinson is editor of Dickinson's FDA Webview ( 
Share this article:
You must be a registered member of MMM to post a comment.

Next Article in As I See It

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in As I See It

As I See It: Patient Centricity

As I See It: Patient Centricity

A patient who is diagnosed earlier and receives the most efficacious treatment is the least expensive

As I See It: FDA's social-media moves

As I See It: FDA's social-media moves

FDA has insisted that its antique regulations can address every new promotional challenge

As I See It: FDA and marketing materials

As I See It: FDA and marketing materials

The more clarity that FDA provides, the more confident companies can be in their medical communications